Blog Exposure – ITUS Presents Positive Data from its Early Cancer Detection Technology at ASCO-SITC Symposium

Stock Monitor: Alliance Data Systems Post Earnings Reporting

LONDON, UK / ACCESSWIRE / January 31, 2018 / Active-Investors.com has just released a free research report on ITUS Corp. (NASDAQ: ITUS).If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ITUS as the Company’s latest news hit the wire. On January 29, 2018, the Company, which is a cancer-focused biotechnology organization, announced that it presented positive data from its ongoing study about its early cancer detection technology at the American Society of Clinical Oncology – Society for Immunotherapy of Cancer (ASCO-SITC) Clinical Immuno-Oncology Symposium in San Francisco, California, on January 26, 2018. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Alliance Data Systems Corporation (NYSE: ADS), which also belongs to the Services sector as the Company ITUS Corp. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=ADS

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, ITUS Corp. most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=ITUS

The ASCO-SITC Clinical Immuno-Oncology Symposium is a three-day meeting that emphasizes on clinical and translational research in immuno-oncology and the implications for clinical care. The data was presented via a poster presentation titled ‘The coupling of MDSCs with a computational analytic method to detect solid tumors’. It highlighted ITUS’ proprietary CchekTM platform that combines the analysis of myeloid-derived suppressor cells (MDSCs) and other subsets of white blood cells with Artificial Intelligence (AI), specifically a neural network (NN), to monitor the patient’s immune system.

Working Towards Early Detection of Cancer

It is well known that when cancer is detected early, that is in Stage I or II, the probability of long-term survival is more than 95%, or even 100% in some cases. But if cancer is detected late, that is Stage III or IV, the chances of long-term survival falls to as low as 10%. Therefore, scientific and investment community show substantial interest in the development of techniques for early cancer detection.

ITUS’ wholly-owned subsidiary, Anixa Diagnostics Corp., is developing the CchekTM platform, which is a series of non-invasive blood tests for the early detection of solid tumor based cancers. It is based on the body’s immunological response to the presence of a malignancy.

Research suggests that there is a dynamic interaction between a patient’s immune system and the existence of a tumor. This interaction leads to subtle changes in the immune system that can be calculated by monitoring and counting circulating white blood cells by using a common laboratory technique known as flow cytometry. Though, simply counting specific cells is not enough to differentiate between a tumor-bearing patient and a healthy individual. However, implementing a neural network to assess the subtle changes and patterns found within the immune system helps the Company to achieve high sensitivity and specificity, which are measures of accuracy of the test.

About the Ongoing Study

The ongoing study enrolled a total of 163 patients, which included 81 cancer patients and 82 healthy donors. As part of the study, collaborators such as the MD Anderson Cancer Center at Cooper, The University of Pennsylvania-Abramson Cancer Center, Virtua Hospital Group, Delaware Valley Urology, and the Wistar Institute provided patient blood samples. Most of the samples collected were from breast cancer and prostate cancer patients, although several other types were also included.
Results from this study supplement the data from the Company’s first cohort, which was released in December 2016. Both these studies were done un-blinded. In the previous study, ITUS reported sensitivity of 92% and specificity of 92%. In this study, it reported a sensitivity of 89% and a specificity of 95%. This little decline in sensitivity is within the margin of error and probably reflects the inclusion of more early stage cancer patients. All cancer patients were biopsy-verified with all clinical stages (I – IV) included. The Area Under the Receiver Operating Characteristic Curve (AUROC), which is a measure of accuracy, was 0.97. It must be noted that AUROC values near 0.50 are poor, while a value greater than 0.90 is considered outstanding.

Technique Can Identify Any Individual With Cancer Regardless Of Tumor Type

The immune system undergoes changes regardless of the location of the tumor and, thus, the patterns indicative of a tumor should exist regardless of the type. The previous study validated that the CchekTM technology works successfully with 15 different types of tumors. Now that additional cancers were included in the study, it shows that ITUS’ technology works with 20 types of cancer from solid tumors. This includes tumors of breast, prostate, lung, colon, pancreatic, melanoma, ovarian, liver, bladder, cervical, endometrial/uterine, gastric, head and neck, testicular, thyroid, osteosarcoma (bone cancer), leiomyosarcoma (cancer of the soft tissue), liposarcoma (cancer of the connective tissue), vulvar, and appendiceal.

Artificial Intelligence Better Than Human Experts

It appears that ITUS’ proprietary AI application is better at making the calls than experienced scientists or physicians. Neutral networks have extraordinary ability to train and analyze the data. One of the most favorable attributes of AI and neural networks is its ability to continuously learn and improve over time in answering the question asked of them. This implies that adding more data would improve the performance further.

ITUS’ Future Plans

Dr. Amit Kumar, President and Chief Executive Officer (CEO) at ITUS, expressed that his team looks forward to publishing this data and also sharing data from other ongoing studies. Besides, he also shared that ITUS’ recently allowed patented claims would help the Company properly protect its technology. At present, ITUS is the only Company that is developing a liquid biopsy diagnostic that incorporates flow cytometry data and AI. He also stated that it is too soon to set the final price for the test but he estimates a price of less than $200.

Stock Performance Snapshot

January 30, 2018 – At Tuesday’s closing bell, ITUS Corp.’s stock fell 2.17%, ending the trading session at $4.05.

Volume traded for the day: 1.62 million shares, which was above the 3-month average volume of 926.82 thousand shares.

Stock performance in the last month – up 65.31%; previous three-month period – up 104.55%; past six-month period – up 412.66%; and year-to-date – up 71.61%

After yesterday’s close, ITUS Corp.’s market cap was at $62.57 million.

The stock is part of the Services sector, categorized under the Business Services industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 487429